Sr Medical Writer - Netherlands

MENARINI Group; Taverne; Remoto; EUR 50.000 - 90.000; Tempo pieno

Descrizione del lavoro

A leading pharmaceutical company is looking for a Senior Medical Writer to manage the creation and editing of essential clinical documents. The ideal candidate should have a strong background in biological sciences and extensive experience in regulatory medical writing, with a clear focus on oncology. As part of the role, you will collaborate with cross-functional teams and ensure compliance with regulatory standards while contributing to significant clinical development programs.

Competenze

• Fluent in English with ability to write complex scientific documents.
• 5-10+ years of relevant experience in regulatory medical writing.
• Thorough understanding of oncology drug development process.

Mansioni

• Plan, write, review, and edit clinical documents like protocols and reports.
• Coordinate timelines and participate in document strategy sessions.
• Conduct literature reviews and prepare clinical trial disclosures.

Conoscenze

Scientific Communication

Technical Writing

Collaboration

Formazione

Bachelor's degree in biological or clinical sciences

Master's, PhD, PharmD, or MD

Strumenti

Microsoft Word

MS SharePoint

Descrizione del lavoro

Senior Medical Writer (Clinical and Regulatory Medical Writing)

Location : Netherlands (remote)

Reports to Head of Medical Writing

As a Sr Medical Writer, you will be responsible for planning, writing, reviewing, editing, formatting, and finalising critical clinical documents such as study reports, protocols, investigator brochures, package inserts, and regulatory submissions. You will ensure that all documents adhere to regulatory standards and accurately reflect the scientific data, supporting our clinical development programs by providing clear and concise communication of scientific information.

If you are a skilled Medical Writer with a passion for scientific communication, we encourage you to apply!

Responsibilities

• Coordinate, author and edit documents used to support clinical trial conduct and reporting including but not limited to :
• Clinical study protocols and clinical protocol amendments
• Clinical study reports
• IND submissions and annual reports
• Integrated summary reports (e.g. summaries of efficacy / safety, clinical overviews)
• NDA, BLA, MAA, (e)CTD submissions
• Health Authority responses
• Participate in relevant document subteam(s) and ensure effective planning and management of timelines for all components of assigned documents across all projects / MWs.
• Participate in document strategy sessions, including messaging, document flow, logic, and consistency for assigned projects.
• Maintain document prototypes and shells, proactively support developing and reviewing standard processes and templates.
• Comply with internal and external processes and guidelines while managing the review process and, on an ongoing basis, resolve issues, errors, or inconsistencies with pertinent team members to ensure timely completion and high quality of assigned documents.
• Review and edit documents as required. Conduct literature reviews, as needed.
• Work effectively and lead cross-functional document working groups.
• Prepare clinical trial disclosures and registration datasets for ClinicalTrials.gov, EudraCT, and CTIS (Clinical Trial Information System) and gain internal / registry approvals; and populate data within websites for public release.

Qualifications

• Fluent in English with proven ability to write complex scientific documents effectively.
• Minimum of a Bachelor's degree in biological or clinical sciences; Graduate degree (Master's, PhD, PharmD, or MD) preferred.
• 5-10+ years of relevant experience in regulatory medical writing.
• Demonstrated ability to review, summarise, and present study data in clinical and regulatory documents.

Drug Development Knowledge

• Thorough understanding of the oncology drug development process, from pre-IND through post-registration.
• Understanding of preclinical, regulatory, pharmacovigilance, drug supply, data sciences, and clinical operations in oncology.

Clinical Information and Strategy :

• Ability to apply knowledge of literature reviews, competitive intelligence, and changing treatment paradigms to support a robust clinical development strategy.
• Ability to interpret, analyse, and present oncology clinical data to inform decision-making and set clinical strategy.
• Understanding of trial design and statistics to apply knowledge to the design of clinical protocols.

Technical Skills and Competencies :

• Hands-on experience performing systematic literature searches, summarising results, and presenting conclusions to various audiences.
• Excellent command of Microsoft Word and authoring documents in an online environment (e.g., MS SharePoint).
• Ability to work effectively in a collaborative team environment, incorporating multiple perspectives.
• Strong organisation, documentation, and communication skills with the ability to multitask.
• Flexibility and ability to adjust to changing demands and priorities, meeting challenges with professionalism.
• Detailed knowledge of GCP, ICH Guidelines, and current global drug regulations.

The Company

Founded in 1886 in Naples under the name of Farmacia Internazionale, Menarini moved in 1915 to Florence where the Group’s headquarters are still located today. High quality therapeutics and diagnostics solutions for patients, ethics as our underlying principle, dedication to innovation and advancement, strong people centricity and environmental sustainability. These five pillars form the foundation of the Menarini Group, an Italian pharmaceutical company with nearly 135 years of history.

Menarini has made a strong commitment to oncology, investing in a pipeline of five investigational compounds for the treatment of a variety of haematological and solid tumours. The acquisition of Stemline Therapeutics in June 2020, further strengthened Menarini’s oncology portfolio, adding both commercial and clinical-stage assets. Tagraxofusp is a novel, first in class targeted therapy for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and to date, the only approved treatment for BPDCN in the U.S. and EU, and the first and only approved CD123-targeted therapy.

Menarini Stemline is an equal-opportunity employer. We celebrate diversity and are committed to creating an inclusive environment for all employees.

J-18808-Ljbffr

J-18808-Ljbffr